Report an error   


Submitted: 18 August 2017 Modified: 18 August 2017
HERDIN Record #: NCR-JAFES-1708181110110

Efficacy of heparinoid supplementation on mortality and disease progression in adults with diabetic kidney disease.

See More

Methodology. Trials evaluating heparinoid supplementation in DKD were included. Two authors performed a literature search with eligible studies undergoing validity screen, data extraction, and statistical analysis. Results were calculated using the Mantel-Haenszel odds ratio for dichotomous variables and the inverse variance method for continuous variables, and pooled using a random or fixed effects model depending on heterogeneity


Results. Twelve trials were included in the analysis. Eight involved sulodexide while two each involved low molecular weight heparin and danaparoid. We found no statistically significant difference between the heparinoid and placebo groups for all-cause mortality (95% CI, HR 0.79 [0.41, 1.53], p=0.49), number of patients reaching therapeutic success (95% CI, OR 0.97 [0.71, 1.33], p=0.87), serum creatinine (95% CI, MD 2.55 umol/L [-0.54, 5.65], p=0.11), and creatinine clearance (95% CI, MD -8.55 mg/min [-18.28, 1.18], p=0.09). We also found no statistically significant difference in urinary albumin excretion rate (UAER) between Type 2 heparinoid-treated DKD patients compared to placebo (95% CI, log transformed MD 0.13 mg/24h [-0.42, 0.68], p=0.65); however, a statistically significant UAER reduction was seen in Type 1 heparinoid-treated DKD patients compared to placebo (95% CI, log-transformed MD -1.5 mg/24h [-2.79, -0.21], p=0.02). This subgroup analysis was performed due to initial heterogeneity (I^2=57%).


Conclusion. Heparinoid supplementation was not associated with statistically significant changes in Type 2 DM patients. However, it may be associated with a statistically significant UAER reduction of approximately 31.62 mg/24 h as compared to placebo in Type 1 DM patients. Due to sparse data on hard clinical outcomes, larger studies are recommended.

To evaluate the safety and efficacy of heparinoid supplementation on all-cause mortality and disease progression in diabetic kidney disease (DKD).

Publication Type
Journal
Publication Sub Type
Journal Article, Original
Title
Journal of the ASEAN Federation of Endocrine Societies
Frequency
Semi-Annual
Publication Date
May-October 2017
Volume
32
Issue
1
Page(s)
20-26

Objectives

To evaluate the safety and efficacy of heparinoid supplementation on all-cause mortality and disease progression in diabetic kidney disease (DKD).

LocationLocation CodeAvailable FormatAvailability
http://www.asean-endocrinejournal.org (532) 6373162 Fulltext External Link (View)
1. Ayodele, OE , Alebiosu, CO , Salako, BL . "Diabetic nephropathy--A review of the natural history, burden, risk factors and treatment" J Natl Med Assoc 96(11): 1445-54, 2004
2. Ritz, E , Rychlik, I , Locatelli, F , Halimi, S . "End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions" Am J Kidney Dis 34(5): 795-808, 1999
3. Mogensen, CE . "How to protect the kidney in diabetic patients: With special reference to IDDM" Diabetes 46(Suppl 2): S104-11, 1997
4. Unnikrishnan , RI , Rema, M , Pradeeepa, R , Deepa, M , Shanthirani, CS , Deepa, R . "Nephropathy in an urban South Indian population: The Chennai Urban Rural Epidemiology Study (CURES 45" Diabetes Care 30(8): 2019-24, 2007
5. Gerstein, HC , Mann, JF , Yi, Q , Zinman, B , Dinneen, SF , Hoogwerf, B . "Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals" JAMA 286(4): 421-6, 2001
6. Strippoli, GF , Craig, M , Deeks, JJ , Schena, FP , Craig, JC . "Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: Systematic review" BMJ 329(7470): 828-38, 2004
7. Bakris, GL , Williams, M , Dworkin, L , Elliott, WJ , Epstein, M , Toto, R . "Preserving renal function in adults with hypertension and diabetes: A consensus approach" Am J Kidney Dis 36(3): 646-61, 2000
8. Van der Pijl, JW , Van der Woude, FJ , Geelhoed-Duijvestijn, PH , Frӧlich, M , Van der Meer, FJ , Lemkes, HH . "Danaparoid sodium lowers proteinuria in diabetic nephropathy" J Am Soc Nephrol 8(3): 456-62, 1997
9. Harenberg, J . "Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide" Med Res Rev 18(1): 1-20, 1998
10. Gambaro, G , Venturini, AP , Noonan, DM , Fries, W , Re, G , Garbisa, S . "Treatment with glycosaminoglycan formulation ameliorates experimental diabetic nephropathy" Kidney Int 46(3): 797-806, 1994
11. Lewis, EJ , Xu, X . "Abnormal glomerular permeability characteristics in diabetic nephropathy: Implications for the therapeutic use of low-molecular weight heparin" Diabetes Care 31(Suppl 2): S202-7, 2008
12. Shu, J , Zeng, LY , Lin, KY , Mu, PW , Zhang, GC , Chen, YM . "Renal protective effects of sulodexide in diabetic rats and its anti-oxidative mechanism" Nan Fang Yi Ke Da Xue Xue Bao (J Southern Med Univ) 29(4): 778-80, 2009
13. Achour, A , Kacem, M , Dibej, K , Skhiri, H , Bouraoui, S , El May, M . "One year course of oral sulodexide in the management of diabetic nephropathy" J Nephrol 18(5): 568-74, 2005
14. Dedov, I , Shestakova, M , Vorontzov, A , Palazzini, E . "A randomized,controlled study of sulodexide therapy for the treatment of diabetic nephropathy" Nephrol Dial Transplant 12(11): 2295-2300, 1997
15. Gambaro, G , Kinalska, I , Oksa, A , Pont, P , Hertlová , M , Olsovsky, J . "Oral sulodexide reduces albuminuriain microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: The Di.N.A.S. randomized trial" J Am Soc Nephrol 13(6): 1615-25, 2002
16. Sulikowska , B , Olejniczak , H , Muszynska, M , Odrowaz-Sypniewska, G , Gaddi, A , Savini, C . "Effect of sulodexide on albuminuria, NAG excretion and glomerular filtration response to dopamine in diabetic patients" Am J Nephrol 26(6): 621-8, 2006
17. Solini, A , Vergnani, L , Ricci, F , Crepaldi, G . "Glycosaminoglycans delay the progression of nephropathy in NIDDM" Diabetes Care 20(5): 819-23, 1997
18. Lewis, EJ , Lewis , JB , Greene, T , Hunsicker, LG , Berl, T , Pohl, MA . "Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: A randomized controlled trial" Am J Kidney Dis 58(5): 729-36, 2011
19. Packham, DK , Wolfe, R , Reutens, AT , Berl, T , Heerspink, HL , Rohde, R . "Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy" J Am Soc Nephrol 23(1): 123-30, 2012
20. Van der Pijl, JW , Lemkes, HHPJ , Frolich, M , Van der Woude, FJ , Van der Meer, FJM , Van Es , LA . "Effect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2" J Am Soc Nephrol 10(6): 1331-6, 1999
21. Tamsma, JT , Van der Woude, FJ , Lemkes, HHPJ . "Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type-1) nephropathy" Nephrol Dial Transplant 11(1): 182-5, 1996
22. Nielsen, S , Schmitz, A , Bacher, T , Rehling, M , Ingerslev, J , Mogensen, CE . "Transcapillary escape rate and albuminuria in type II diabetes. Effects of short term treatment with low-molecular weight heparin (short communication)" Diabetologia 42(1): 60-7, 1999
23. Heerspink, HL , Greene, T , Lewis , JB , Raz, I , Rohde, RD , Hunsicker, LG . "Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria" Nephrol Dial Transplant 23(6): 1946-54, 2008
24. Ruggenenti, P , Remuzzi, G . "Nephropathy of type 1 and type 2 diabetes: Diverse pathophysiology, same treatment? " Nephrol Dial Transplant 15(12): 1900-2, 2000
25. Wu, AYT , Kong, NCT , de Leon, FA , Pan, CY , Tai, TY , Yeung, VTF . "An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: The MicroAlbuminuria Prevalence (MAP) Study" Diabetologia 48(8): 17-26, 2005
26. Simmonds, M . "Quantifying the risk of error when interpreting funnel plots" Syst Rev 11(4): 24, 2015

Copyright © One Window Project 2018. All rights reserved.